Journal of Integrative Neuroscience

*J. Integr. Neurosci.* **2024**; 23(5): 94
https://doi.org/10.31083/j.jin2305094

*Editorial*

# Bridging the Gap: Translational Medicine and Novel Therapies in Neuromuscular Diseases

Massimiliano Filosto[1,2,*]

[1]Department of Clinical and Experimental Sciences, University of Brescia, 25100 Brescia, Italy
[2]NeMo-Brescia Clinical Center for Neuromuscular Diseases and ERN Euro-NMD Center ASST Spedali Civili, 25100 Brescia, Italy
*Correspondence: massimiliano.filosto@unibs.it (Massimiliano Filosto)

Academic Editor: Gernot Riedel
Submitted: 6 March 2024 Accepted: 12 March 2024 Published: 30 April 2024

Neuromuscular diseases encompass a wide range of disorders that affect motor neurons, peripheral nerves, and muscles. The impact of most of these conditions can be profound, often leading to progressive muscle weakness, loss of mobility, and, in severe cases, respiratory failure and premature death.

In the intricate tapestry of medical research, the journey from bench to bedside is often fraught with challenges. Yet, in the field of neuromuscular diseases, translational medicine emerges as a beacon of hope, bridging the gap between scientific discovery and clinical application. As we navigate the complex landscape of these debilitating conditions, it is imperative to recognize and harness the transformative power of translational medicine in advancing the frontiers of diagnosis, treatment, and ultimately, patient care.

At its core, translational medicine embodies the seamless integration of basic science insights into clinical practice, with the overarching goal of improving patient outcomes. In the context of neuromuscular diseases, where the interplay of genetic, molecular, and physiological factors intricately shapes disease progression, translational research plays a pivotal role in unraveling the underlying mechanisms and identifying novel therapeutic targets.

One of the most challenging aspects of neuromuscular diseases lies in biomarker discovery. Biomarkers, measurable indicators of biological processes or disease states, serve as invaluable tools for early diagnosis, prognostic assessment, and monitoring treatment response. Through collaborative efforts between basic scientists and clinical researchers, biomarker discovery initiatives need to be implemented in order to offer insights into disease pathogenesis and facilitate the development of targeted therapies tailored to individual patient profiles.

Translational medicine serves as a catalyst for the conversion of cutting-edge technologies into clinical practice. From next-generation sequencing and gene editing techniques, to advanced imaging modalities and wearable devices, the arsenal of tools at the disposal of translational researchers continues to expand, enabling precision diagnostics, personalized treatment strategies, and real-time monitoring of disease progression. By harnessing the transformative potential of these technologies, clinicians can deliver tailored interventions that optimize therapeutic efficacy while minimizing adverse effects, thereby revolutionizing the standard of care for patients with neuromuscular diseases.

However, the journey from bench to bedside is not without its hurdles. Translational research in neuromuscular diseases faces myriad challenges, including the need for interdisciplinary collaboration, the translation of preclinical findings into clinically viable therapies, and the imperative to navigate regulatory pathways and ensure patient safety. Moreover, disparities in research funding and access to resources pose barriers to progress, underscoring the importance of advocacy and investment in translational initiatives aimed at addressing unmet medical needs.

As we chart the course forward, it is necessary that we redouble our efforts to bolster translational research in neuromuscular diseases. By fostering collaborative partnerships between academia, industry, and patient advocacy groups, we can accelerate the pace of discovery, drive innovation, and ultimately transform the lives of individuals affected by these devastating conditions. Together, let us seize the opportunity afforded by translational medicine to usher in a new era of hope and healing, in which breakthroughs at the bench translate into tangible improvements in patient care at the bedside.

One of the most tangible effects of the translational effort in the field of neuromuscular diseases falls in the therapeutic field. Historically, the landscape of treatment for neuromuscular diseases has long been characterized by challenges and limitations; the treatment options have been limited, focusing primarily on symptom management and supportive care. However, a wave of novel therapies is now heralding a new era of possibility and promise for those affected by these conditions.

One of the most remarkable breakthroughs has been the advent of molecular- and gene-based treatments. Antisense oligonucleotides (ASOs) are synthetic molecules designed to modulate gene expression by targeting specific RNA sequences. This targeted approach has demonstrated remarkable efficacy in some neuromuscular diseases. In spinal muscular atrophy (SMA), a devastating motor neuron disease, the introduction of gene-targeted therapies has transformed the prognosis for affected individuals. Drugs like nusinersen and risdiplam have shown unprecedented efficacy in improving motor function and prolonging survival in SMA patients, offering a glimmer of hope where there was once only despair [1–3]. In Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disorder caused by mutations in the dystrophin gene, drugs like eteplirsen, viltolarsen, and golodirsen seem to have the potential to slow disease progression and preserve muscle function, representing a significant stride forward in the quest for effective treatments [4,5].

Gene therapy, which involves delivering functional genes to replace or compensate for defective ones, holds immense promise for conditions previously considered incurable. By delivering a functional copy of the survival motor neuron 1 (*SMN1*) gene—the gene mutated in SMA—directly to affected cells, therapy with onasemnogene abeparvovec was designed to address the root cause of the disease, restoring the production of the SMN protein essential for motor neuron function [6]. The impact of onasemnogene abeparvovec on disease progression is evidenced by clinical trials that demonstrated significant improvements in motor function and survival rates in infants with SMA. Mini-dystrophin therapy represents a paradigm shift in the management of DMD, by aiming to restore functional dystrophin expression and halt disease progression at its core [7]. By delivering, using viral vectors, a shortened, functional version of the dystrophin gene into muscle cells, this therapy bypasses the genetic defect responsible for DMD, effectively replacing the missing or defective dystrophin protein. The result is the restoration of structural integrity to muscle fibers, mitigating the debilitating effects of the disease, and offering patients the possibility of improved muscle function and quality of life. The promise of mini-dystrophin therapy is underscored by encouraging preclinical and clinical trial data that have demonstrated meaningful improvements in muscle strength, function, and overall clinical outcomes in individuals with DMD. Moreover, ongoing research efforts are focused on refining treatment protocols, optimizing vector delivery methods, and expanding eligibility criteria to encompass a broader spectrum of patients, including those with advanced disease stages.

Advancements in precision medicine and personalized therapies are reshaping the treatment landscape for neuromuscular diseases. With a deeper understanding of the genetic underpinnings of these conditions, researchers can tailor interventions to individual patients based on the patients' unique genetic profiles. This tailored approach not only enhances treatment efficacy but also minimizes the risk of adverse effects, marking a paradigm shift from traditional, one-size-fits-all approaches.

However, despite the tremendous progress achieved so far, challenges remain to widespread adoption of novel therapies for neuromuscular diseases. Access barriers, including high treatment costs and limited availability, threaten to widen existing disparities in healthcare access and perpetuate inequalities in treatment outcomes. Moreover, ongoing research is needed to address remaining gaps in our understanding of disease mechanisms and to optimize therapeutic strategies for maximum efficacy.

In conclusion, the emergence of novel therapies for neuromuscular diseases represents a beacon of hope for millions of individuals worldwide. From gene-based treatments to precision-medicine approaches, the landscape of disease management is undergoing a profound transformation. As we continue to push the boundaries of medical science, it is imperative that we prioritize accessibility, equity, and innovation to ensure that these groundbreaking therapies reach all those in need.

## Author Contributions

MF—Conceptualization, Writing, Original draft.

## Ethics Approval and Consent to Participate

Not applicable.


## Acknowledgment

Not applicable.

## Funding

This research received no external funding.


## Conflict of Interest

The author declares no conflict of interest. Massimiliano Filosto is serving as one of the Editorial Board members of this journal. The author declares that Massimiliano Filosto had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Gernot Riedel.

## References


[1] Pane M, Coratti G, Sansone VA, Messina S, Catteruccia M, Bruno C, *et al*. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function. European Journal of Neurology. 2023; 30: 1755–1763.

[2] Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, *et al*. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. Journal of Neurology, Neurosurgery, and Psychiatry. 2020; 91: 1166–1174.

[3] Qiao Y, Chi Y, Gu J, Ma Y. Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Brain Sciences. 2023; 13: 1419.

[4] Iff J, Zhong Y, Tuttle E, Gupta D, Paul X, Erik Henricson. Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA. Journal of Comparative Effectiveness Research. 2023; 12: e230086.

[5] Saad FA, Siciliano G, Angelini C. Advances in Dystrophinopathy Diagnosis and Therapy. Biomolecules. 2023; 13: 1319.
[6] Pane M, Berti B, Capasso A, Coratti G, Varone A, D'Amico A, *et al*. Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies. eClinicalMedicine. 2023; 59: 101997.
[7] Wang X, Zhu Y, Liu T, Zhou L, Fu Y, Zhao J, *et al*. Duchenne muscular dystrophy treatment with lentiviral vector containing mini-dystrophin gene in vivo. MedComm. 2024; 5: e423.